BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1055 related articles for article (PubMed ID: 33006257)

  • 1. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
    Pudil R; Mueller C; Čelutkienė J; Henriksen PA; Lenihan D; Dent S; Barac A; Stanway S; Moslehi J; Suter TM; Ky B; Štěrba M; Cardinale D; Cohen-Solal A; Tocchetti CG; Farmakis D; Bergler-Klein J; Anker MS; Von Haehling S; Belenkov Y; Iakobishvili Z; Maack C; Ciardiello F; Ruschitzka F; Coats AJS; Seferovic P; Lainscak M; Piepoli MF; Chioncel O; Bax J; Hulot JS; Skouri H; Hägler-Laube ES; Asteggiano R; Fernandez TL; de Boer RA; Lyon AR
    Eur J Heart Fail; 2020 Nov; 22(11):1966-1983. PubMed ID: 33006257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC).
    Čelutkienė J; Pudil R; López-Fernández T; Grapsa J; Nihoyannopoulos P; Bergler-Klein J; Cohen-Solal A; Farmakis D; Tocchetti CG; von Haehling S; Barberis V; Flachskampf FA; Čeponienė I; Haegler-Laube E; Suter T; Lapinskas T; Prasad S; de Boer RA; Wechalekar K; Anker MS; Iakobishvili Z; Bucciarelli-Ducci C; Schulz-Menger J; Cosyns B; Gaemperli O; Belenkov Y; Hulot JS; Galderisi M; Lancellotti P; Bax J; Marwick TH; Chioncel O; Jaarsma T; Mullens W; Piepoli M; Thum T; Heymans S; Mueller C; Moura B; Ruschitzka F; Zamorano JL; Rosano G; Coats AJS; Asteggiano R; Seferovic P; Edvardsen T; Lyon AR
    Eur J Heart Fail; 2020 Sep; 22(9):1504-1524. PubMed ID: 32621569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
    Lyon AR; Dent S; Stanway S; Earl H; Brezden-Masley C; Cohen-Solal A; Tocchetti CG; Moslehi JJ; Groarke JD; Bergler-Klein J; Khoo V; Tan LL; Anker MS; von Haehling S; Maack C; Pudil R; Barac A; Thavendiranathan P; Ky B; Neilan TG; Belenkov Y; Rosen SD; Iakobishvili Z; Sverdlov AL; Hajjar LA; Macedo AVS; Manisty C; Ciardiello F; Farmakis D; de Boer RA; Skouri H; Suter TM; Cardinale D; Witteles RM; Fradley MG; Herrmann J; Cornell RF; Wechelaker A; Mauro MJ; Milojkovic D; de Lavallade H; Ruschitzka F; Coats AJS; Seferovic PM; Chioncel O; Thum T; Bauersachs J; Andres MS; Wright DJ; López-Fernández T; Plummer C; Lenihan D
    Eur J Heart Fail; 2020 Nov; 22(11):1945-1960. PubMed ID: 32463967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [MODERN ASPECTS OF DIAGNOSIS AND TREATMENT OF HEART FAILURE, AS A MANIFESTATION OF ANTHRACYCLINE CARDIOTOXICITY (REVIEW)].
    Saganelidze K; Kavtaradze N
    Georgian Med News; 2018 May; (278):87-93. PubMed ID: 29905551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.
    Bergler-Klein J; Rainer PP; Wallner M; Zaruba MM; Dörler J; Böhmer A; Buchacher T; Frey M; Adlbrecht C; Bartsch R; Gyöngyösi M; Fürst UM
    Wien Klin Wochenschr; 2022 Sep; 134(17-18):654-674. PubMed ID: 35507087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Biomarkers to Evaluate Cardiotoxicity.
    Upshaw JN
    Curr Treat Options Oncol; 2020 Aug; 21(10):79. PubMed ID: 32767198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biomarkers in cardio-oncology patients].
    Totzeck M; Glas M; Rassaf T
    Internist (Berl); 2020 Nov; 61(11):1114-1119. PubMed ID: 33025124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond.
    Attanasio U; Di Sarro E; Tricarico L; Di Lisi D; Armentaro G; Miceli S; Fioretti F; Deidda M; Correale M; Novo G; Sciacqua A; Nodari S; Cadeddu C; Tocchetti CG; Palazzuoli A; Mercurio V
    Biomolecules; 2024 Feb; 14(2):. PubMed ID: 38397436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients.
    Tajiri K; Aonuma K; Sekine I
    Jpn J Clin Oncol; 2017 Aug; 47(8):678-682. PubMed ID: 28505345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying cancer patients at risk for cardiotoxicity.
    Salvatici M; Sandri MT
    Future Oncol; 2015; 11(14):2077-91. PubMed ID: 26198838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
    Lyon AR; López-Fernández T; Couch LS; Asteggiano R; Aznar MC; Bergler-Klein J; Boriani G; Cardinale D; Cordoba R; Cosyns B; Cutter DJ; de Azambuja E; de Boer RA; Dent SF; Farmakis D; Gevaert SA; Gorog DA; Herrmann J; Lenihan D; Moslehi J; Moura B; Salinger SS; Stephens R; Suter TM; Szmit S; Tamargo J; Thavendiranathan P; Tocchetti CG; van der Meer P; van der Pal HJH;
    Eur Heart J; 2022 Nov; 43(41):4229-4361. PubMed ID: 36017568
    [No Abstract]   [Full Text] [Related]  

  • 12. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
    Lyon AR; López-Fernández T; Couch LS; Asteggiano R; Aznar MC; Bergler-Klein J; Boriani G; Cardinale D; Cordoba R; Cosyns B; Cutter DJ; de Azambuja E; de Boer RA; Dent SF; Farmakis D; Gevaert SA; Gorog DA; Herrmann J; Lenihan D; Moslehi J; Moura B; Salinger SS; Stephens R; Suter TM; Szmit S; Tamargo J; Thavendiranathan P; Tocchetti CG; van der Meer P; van der Pal HJH;
    Eur Heart J Cardiovasc Imaging; 2022 Sep; 23(10):e333-e465. PubMed ID: 36017575
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?
    Levis BE; Binkley PF; Shapiro CL
    Lancet Oncol; 2017 Aug; 18(8):e445-e456. PubMed ID: 28759384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).
    Zamorano JL; Lancellotti P; Rodriguez Muñoz D; Aboyans V; Asteggiano R; Galderisi M; Habib G; Lenihan DJ; Lip GYH; Lyon AR; Lopez Fernandez T; Mohty D; Piepoli MF; Tamargo J; Torbicki A; Suter TM;
    Eur Heart J; 2016 Sep; 37(36):2768-2801. PubMed ID: 27567406
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology.
    Kostakou PM; Kouris NT; Kostopoulos VS; Damaskos DS; Olympios CD
    Heart Fail Rev; 2019 Jan; 24(1):91-100. PubMed ID: 30073443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer Therapy-Related Cardiac Dysfunction: Unresolved Issues.
    Marwick TH
    Can J Cardiol; 2016 Jul; 32(7):842-6. PubMed ID: 27343742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart failure and chemotherapeutic agents.
    Piper S; McDonagh T
    Future Cardiol; 2015 Jul; 11(4):453-70. PubMed ID: 26234158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Biomarkers in Cardio-Oncology.
    Ananthan K; Lyon AR
    J Cardiovasc Transl Res; 2020 Jun; 13(3):431-450. PubMed ID: 32642841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of cardiac biomarkers in cardio-oncology.
    Riddell E; Lenihan D
    Curr Probl Cancer; 2018 Jul; 42(4):375-385. PubMed ID: 30126650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.